Lung cancer

April 15, 2022

News in Brief, April 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 22, 2021

Trial Spotlight: Helena Yu on the EA5182 Trial for Metastatic, EGFR-Mutant Non-Small Cell Lung Cancer

This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
September 30, 2021

A New Guide Encourages the Use of Language that is Respectful of Patients, Free of Stigma, Inclusive, and Equitable

A new Language Guide provides guidelines on best practices with common phrases to use during presentations at medical conferences and within submitted abstracts
September 30, 2021

News in Brief, September 2021

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
May 28, 2021

ECOG-ACRIN Names Vanderbilt University’s Christine Lovly as Its 2021 Young Investigator of the Year

Dr. Lovly is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a highly prestigious recognition of research excellence
March 31, 2021

Now Enrolling: PrE0506 / DREAM3R for Patients with Malignant Pleural Mesothelioma

This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
December 14, 2020

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020

ECOG-ACRIN Names University of Pennsylvania’s Bonnie Ky As Its Young Investigator of the Year

Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
June 10, 2020

Now Enrolling: EA5181 for Patients with Stage 3 Non-Small Cell Lung Cancer

This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody